Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma making solid progress on cancer treatments, Cantor says

Cantor Fitzgerald has repeated a 'buy' rating on Redx Pharma after the company reported progress on the development of cancer treatments
Redx
Cantor reiterates a 'buy' rating on Redx Pharma

Redx Pharma Plc (LON:REDX) has enjoyed a productive year with two potentially best-in-class cancer treatments, Cantor Fitzgerald said today.

In its full year results yesterday, the drug maker reported progress of its development of its treatments.

The group's pipeline includes the Porcupine RXC004 treatment for pancreatic, biliary and gastric cancer, which will enter its first in-human studies following a clinical trial application (CTA) submission in the second quarter.

Redx is also developing leukaemia treatment BTK RXC005 and plans to make an investigational new drug application and CTA towards the end of 2017.

Cantor Fitzgerald reiterated a ‘buy’ rating on the stock and a target price of 105.0p, saying 2016 has been an “important year for Redx with solid process from the discovery engine” with molecules in focus areas of oncology and immunology.

“The first of these (a porcupine inhibitor) has overcome limitations which have blighted this approach (wnt pathway) elsewhere and is scheduled to enter the clince in mid-2017 targeting difficult to treat cancers.

“Elsewhere the BTK programme is progressing towards the clinic and remains a highly attractive asset in a very lucrative area (haematological cancers).”

Cantor said its recent £12mln fundraising has provided Redx with sufficient funds to allow it to deliver its lead RXC004 into clinic trials as well as progress the development of RXC005, which is expected to enter the clinic in early 2018.

The broker also welcomed Redx’s restructuring, which includes plans to cut jobs by 60%, to achieve estimated cost savings of about £4.2mln. 

“Redx has now refocused, is aiming to material reduce headcount (circa 60%), principally to capitalise on its clinical assets, while retaining its impressive research engine and funding its anti-infectives research through external collaborations.”

View full REDX profile

Redx Pharma Plc Timeline

Related Articles

Paradigm Biopharmaceuticals [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
01:00
Find out more from Paul Rennie at Proactive's CEO Sessions.
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use